ART OF MEDICINE 2017

 

GENDER FEATURES OF IMMUNE DISORDERS IN METABOLIC SYNDROME

 

S.V. Fedorov1, I.V. Kozlova1, N.Yu. Senyshyn1, V.M. Kulaets1, N.M. Kulaets1.,

I.I. Gamorak2

            1SHEI «Ivano-Frankivsk National Medical University»

            2Ivano-Frankivsk Regional Cardiology Hospital, Ivano-Frankivsk, Ukraine.

 

Abstract

Abstract. The metabolic syndrome (MetS) has emerged as an important cluster of risk factors for atherosclerotic disease. Common features are central (abdominal) obesity, insulin resistance, hypertension, and dyslipidemia, namely high triglycerides and low high-density lipoprotein cholesterol. Many studies showed the high prevalence of metabolic syndrome among postmenopausal women, which varies from 32.6% to 41.5%. Chronic inflammation and immune system disturbances may represent a triggering factor in the origin of the metabolic syndrome: stimuli such as overnutrition, physical inactivity, and ageing would result in cytokine hypersecretion and eventually lead to insulin resistance and diabetes in genetically or metabolically predisposed individuals.       

Aim of study: evaluation of gender features of immune parameters in patients with metabolic syndrome.

Materials and methods. 130 patients with MetS were observed – 24 males and 106 females. All females were divided into two groups: 80 patients in physiological menopause and 26 without it. 21 practically healthy females without signs of MetS were the control group. The immunological parameters of 1-st level were studied.

Results. MetS in menopausal woman is characterized of increase of Ig A, Ig G and Ig M in blood plasma and growth of pathological middle and low-molecular immune complexes. Physiological high-molecular complexes were without changes.

Conclusion. The features of menopausal metabolic syndrome are high levels in serum of Ig A, Ig G and Ig M, and increased concentration of middle and low-molecular circulating immune complexes.

 

Key words: metabolic syndrome, immunity, gender.

 

Full text: PDF (Rus)

References
  1. European Heart Network. European Cardiovascular Disease Statistics. 2008 – ESC, 2008. – 38 p.
  2. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) /Joep Perk , Guy De Backer, Helmut Gohlke [et al.] //European Heart Journal. – 2012. –Vol. 33. –P. 1635–1701.
  3. Чекальская, Н. А. Патогенетическое обоснование комплексной фармакотерапевтической коррекции метаболических нарушений у женщин с менопаузальным метаболическим синдромом  / Н. А. Чекальская, О. В. Корпачева-Зиныч // Здоровье женщины. – 2009. – № 5. – С.153-160.
  4. Erik B.A. Sex differences of endogenous sex hormones iand risk of type 2 diabetes / B.A. Erik, L. Ding, M. Yijiing Song //JAMA. – – Vol.295. –P.1288-1299.
  5. Metabolic syndrome and risk of incident cardiovascular events and death / S. Gami, B. J.Witt, D. E. Howard [et al.] // J. Am. Coll. Cardiol. — 2007. — Vol.49. — P. 403–414.
  6. Lovejoy J. The influence of sex hormones on obesity across female life / J.Lovejoy //J. Women Health. -1998. –Vol.7. –P.1247-1256.
  7. Ong K.L.Gender differences in BP control and cardiovascular risk factors in Americans with diagnosed hypertension. / K.L. Ong, A.W-K. Tso, K.S. Lam, B.M.Cheung // -2008. –Vol. 123. –P.12-16.
  8. Recent changes in cardiovascular risk factors among women and men. / J.K.Kim, D. Alley, T. Seeman [et al.] //J Women’s Health (Larchmont). – –Vol.12. –P.12-16.
  9. Andersen C.J. Impact of Obesity and Metabolic Syndrome on Immunity./ C.J. Andersen, K.E. Murphy, M. Fernandez //Advances in Nutrition. – 2016. – Vol.7. – P.66-75.
  10. European Medicines Agency. ICH Harmonised Tripartite Guideline E6: Note for Guidance on Good Clinical Practice (PMP/ICH/135/95). – London: European Medicines Agency, 2002. – 46 p.
  11. Laboratory investigations in clinical immunology: methods, pitfails and clinical indications: a second IUIS WHO report // Clin. Immunol. Immunopathol. – 1988. – Vol. 49. – P. 478-497.
  12. Savage P.D. Prevalence of metabolic syndrome  in  cardiac  rehabilitation/secondary prevention programs. / P.D. Savage, J.A. Banzer, G.J. Balady //Am. Heart J. – 2005. – 149. – P.627-631.
  13. Marjani A. The Metabolic Syndrome among Postmenopausal Women in Gorgan. / Marjani, S. Moghasemi //Int. J. Endocrinol. – 2012. – Vol. 202. –P. 6-16.
  14. Teppala S. Bisphenol A and Metabolic Syndrome: Results from NHANES. / S.Teppala , S. Madhavan , Shankar A. // J. Endocrinol. – 2012. –Vol.59. – P.: 80-81.
  15. Weis S.M. Vascular permeability in cardiovascular disease and cancer. / S.M.Weis // Opin. Hematol. – 2008. – Vol.15. – P.243–249.
  16. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. / S. Tsimikas, C. Bergmark, R.W. Beyer [et al.] // Am. Coll. Cardiol. – 2003. –Vol.41. –P.360–370.